Spots Global Cancer Trial Database for refractory melanoma

Every month we try and update this database with for refractory melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Study of CP-675,206 in Refractory Melanoma	NCT00254579	Refractory Mela...	CP-675,206	18 Years -	AstraZeneca
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER	NCT02029729	Metastatic or I... Relapsed, Refra...	omaveloxolone	18 Years - 75 Years	Biogen
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER	NCT02029729	Metastatic or I... Relapsed, Refra...	omaveloxolone	18 Years - 75 Years	Biogen
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04284774	Malignant Solid... Recurrent Adren... Recurrent Ectom... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Melan... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Recurrent WHO G... Refractory Adre... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Mela... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory WHO ...	Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Tipifarnib	12 Months - 21 Years	National Cancer Institute (NCI)
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases	NCT03175432	BRAF V600 Wild ... Clinical Stage ... Intracranial Me... Metastatic Mali... Metastatic Mela... Pathologic Stag... Refractory Mela...	Atezolizumab Bevacizumab Cobimetinib Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
A Study of SEA-CD40 Given With Other Drugs in Cancers	NCT04993677	Melanoma Carcinoma, Non-...	SEA-CD40 pembrolizumab pemetrexed carboplatin	18 Years -	Seagen Inc.
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER	NCT02029729	Metastatic or I... Relapsed, Refra...	omaveloxolone	18 Years - 75 Years	Biogen
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: